Abstract: A recombinant vesicular stomatitis vims (rVSV) carrying one or more genes that encode for the spike protein of SARS-CoV-2 or for both the S protein and the envelope protein of the SARS-CoV-2. Vaccines, regimens and kits having the rVSV are used for the prevention of infections caused by SARS-CoV-2.

Abstract: A recombinant vesicular stomatitis vims (rVSV) carrying at least one gene that encodes for a MERS-CoV structural protein or modifications thereof. Vaccines or immunogenic compositions against MERS-CoV, and prime boost immunization platforms a prime boost immunization combination against MERS-CoV including: (a) a prime vaccine or immunogenic composition comprising a rVSV carrying at least one gene that encodes for a MERS-CoV structural protein or modifications thereof, and (b) a boost vaccine or immunogenic composition comprising a rVSV carrying the same at least one gene that encodes for a MERS-CoV structural protein or modifications thereof. The at least one gene can be genetically modified to encode a modified MERS-CoV structural protein that elevates glycoprotein synthesis and trigger efficient humoral immune response.

Abstract: A recombinant vesicular stomatitits virus (rVSV) having a Zika virus (ZIKV) envelope (E) gene, a prime boost immunization combination against ZIKV including: (a) a prime vaccine or immunogenic composition comprising a recombinant vesicular stomatitis virus (rVSV) carrying a ZIKV envelope (E) protein, and (b) a boost vaccine or immunogenic composition comprising a rVSV carrying the same ZIKV E protein. The ZIKV gene can be genetically modified to encode a modified ZIKV E protein that elevates glycoprotein synthesis and trigger efficient humoral immune response.